Previous studies have shown that TNF-inhibitors can improve endothelial function and decrease cardiovascular events in responder patients, highlighting the pro-atherogenic effect of TNFα in RA [9, 10]. The gene discussed is TNF; the disease is rheumatoid arthritis.